Palvella Therapeutics (PVLA) News Today $74.68 +4.78 (+6.84%) As of 02:55 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PVLA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for ...October 13 at 9:14 AM | markets.businessinsider.comPalvella Therapeutics Secures Second Year of FDA Funding for Phase 3 SELVA Trial of QTORIN™ RapamycinOctober 13 at 7:51 AM | quiverquant.comQU.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic MalformationsOctober 13 at 7:30 AM | globenewswire.comPalvella Therapeutics (NASDAQ:PVLA) Shares Down 5.9% - What's Next?October 11 at 11:45 AM | marketbeat.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 11 at 4:07 AM | marketbeat.comPalvella Therapeutics' (PVLA) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 10 at 6:21 AM | marketbeat.comPalvella Therapeutics price target raised to $90 from $66 at CanaccordOctober 9, 2025 | msn.comPalvella Therapeutics price target raised to $120 from $70 at Cantor FitzgeraldOctober 7, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Trading 6.6% Higher - Here's What HappenedOctober 7, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High - Here's WhyOctober 6, 2025 | marketbeat.comStrid Group LLC Lowers Stake in Palvella Therapeutics, Inc. $PVLAOctober 5, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Stock Price Expected to Rise, Truist Financial Analyst SaysOctober 4, 2025 | americanbankingnews.comPalvella Therapeutics price target raised to $80 from $56 at TruistOctober 2, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $80.00October 2, 2025 | marketbeat.comCritical Review: Palvella Therapeutics (NASDAQ:PVLA) and Bionano Genomics (NASDAQ:BNGO)October 2, 2025 | americanbankingnews.comPalvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst UpgradeSeptember 29, 2025 | marketbeat.comEquities Analysts Offer Predictions for PVLA FY2028 EarningsSeptember 29, 2025 | marketbeat.comChardan Capital Maintains Palvella Therapeutics (PVLA) Buy RecommendationSeptember 26, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00 at Chardan CapitalSeptember 26, 2025 | marketbeat.comGoldman Sachs Group Inc. Makes New $533,000 Investment in Palvella Therapeutics, Inc. $PVLASeptember 26, 2025 | marketbeat.comHC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy RecommendationSeptember 26, 2025 | msn.comPalvella Therapeutics price target raised to $95 from $75 at H.C. WainwrightSeptember 25, 2025 | msn.comPalvella Expands QTORIN Gel Program for Rare DiseaseSeptember 25, 2025 | msn.comPalvella Therapeutics expands QTORIN rapamycin development programSeptember 24, 2025 | msn.comPalvella Therapeutics price target raised to $80 from $60 at StifelSeptember 24, 2025 | msn.comStifel Nicolaus Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $80.00September 24, 2025 | marketbeat.comPalvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease ...September 24, 2025 | finance.yahoo.comPalvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved TherapiesSeptember 24, 2025 | globenewswire.comPalvella Therapeutics: QTORIN Nears Phase 3 Readout For MLMSeptember 22, 2025 | seekingalpha.comClio Asset Management LLC Acquires Shares of 91,508 Palvella Therapeutics, Inc. $PVLASeptember 21, 2025 | marketbeat.comPalvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin DisorderSeptember 21, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Sets New 1-Year High - Here's What HappenedSeptember 20, 2025 | marketbeat.comPalvella Therapeutics announces publication of literature review of rapamycinSeptember 17, 2025 | msn.comPalvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real ...September 17, 2025 | finance.yahoo.comPalvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted TherapySeptember 17, 2025 | globenewswire.comPalvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Rating of "Buy" from BrokeragesSeptember 17, 2025 | marketbeat.comPalvella Therapeutics Inc.: Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous MalformationsSeptember 15, 2025 | finanznachrichten.dePalvella Therapeutics completes enrollment in Phase 2 TOIVA trial of QTORINSeptember 15, 2025 | msn.comPalvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous MalformationsSeptember 15, 2025 | globenewswire.comWoodline Partners LP Invests $5.44 Million in Palvella Therapeutics, Inc. $PVLASeptember 15, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Trading Down 6% - Here's What HappenedSeptember 14, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High - What's Next?September 13, 2025 | marketbeat.comPalvella Therapeutics (NASDAQ:PVLA) Coverage Initiated by Analysts at OppenheimerSeptember 11, 2025 | marketbeat.comOppenheimer Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform RecommendationSeptember 9, 2025 | msn.comPalvella Therapeutics initiated with an Outperform at OppenheimerSeptember 9, 2025 | msn.comPalvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation OfficerSeptember 7, 2025 | msn.comPalvella Therapeutics (NASDAQ:PVLA) Trading Up 7.7% - Should You Buy?September 5, 2025 | marketbeat.comAWM Investment Company Inc. Takes Position in Palvella Therapeutics, Inc. $PVLASeptember 5, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Has $19.31 Million Stock Holdings in Palvella Therapeutics, Inc. $PVLASeptember 4, 2025 | marketbeat.comPalvella Therapeutics appoints Osborne as Chief Innovation OfficerSeptember 3, 2025 | msn.com Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVLA Media Mentions By Week PVLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PVLA News Sentiment▼0.660.77▲Average Medical News Sentiment PVLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PVLA Articles This Week▼115▲PVLA Articles Average Week Get the Latest News and Ratings for PVLA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Palvella Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CNTA News Today XENE News Today CGON News Today TARS News Today RARE News Today MOR News Today KNSA News Today IMVT News Today HCM News Today OGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PVLA) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
